Indaptus Therapeutics (INDP) Competitors $7.35 +0.19 (+2.65%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$7.23 -0.12 (-1.69%) As of 08/22/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. ADAP, EDSA, LPCN, BLRX, MTEX, LIXT, NRSN, COCP, ATHA, and AIMDShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Adaptimmune Therapeutics (ADAP), Edesa Biotech (EDSA), Lipocine (LPCN), BioLineRx (BLRX), Mannatech (MTEX), Lixte Biotechnology (LIXT), NeuroSense Therapeutics (NRSN), Cocrystal Pharma (COCP), Athira Pharma (ATHA), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors Adaptimmune Therapeutics Edesa Biotech Lipocine BioLineRx Mannatech Lixte Biotechnology NeuroSense Therapeutics Cocrystal Pharma Athira Pharma Ainos Adaptimmune Therapeutics (NASDAQ:ADAP) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends. Do analysts rate ADAP or INDP? Adaptimmune Therapeutics currently has a consensus price target of $1.35, suggesting a potential upside of 2,275.51%. Indaptus Therapeutics has a consensus price target of $238.00, suggesting a potential upside of 3,138.10%. Given Indaptus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Indaptus Therapeutics is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ADAP or INDP? Adaptimmune Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Is ADAP or INDP more profitable? Indaptus Therapeutics has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -260.82%. Adaptimmune Therapeutics' return on equity of -163.73% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-260.82% -163.73% -75.83% Indaptus Therapeutics N/A -612.59%-243.78% Which has higher earnings and valuation, ADAP or INDP? Indaptus Therapeutics has lower revenue, but higher earnings than Adaptimmune Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$178.03M0.08-$70.81M-$0.65-0.09Indaptus TherapeuticsN/AN/A-$15.02M-$37.66-0.20 Do institutionals & insiders believe in ADAP or INDP? 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 12.7% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 20.8% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor ADAP or INDP? In the previous week, Adaptimmune Therapeutics had 12 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 12 mentions for Adaptimmune Therapeutics and 0 mentions for Indaptus Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.29 beat Indaptus Therapeutics' score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Adaptimmune Therapeutics Neutral Indaptus Therapeutics Neutral SummaryAdaptimmune Therapeutics beats Indaptus Therapeutics on 9 of the 15 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.92M$2.57B$5.76B$9.58BDividend YieldN/A1.67%4.41%4.10%P/E Ratio-0.2022.6131.1026.04Price / SalesN/A554.26433.45102.77Price / CashN/A180.4637.7358.48Price / Book-4.875.939.536.61Net Income-$15.02M$31.83M$3.26B$265.56M7 Day Performance-4.23%1.89%2.10%1.97%1 Month Performance-29.73%1.33%2.81%-0.36%1 Year Performance-83.90%8.84%30.56%19.03% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.6753 of 5 stars$7.35+2.7%$238.00+3,138.1%-83.5%$7.92MN/A-0.206ADAPAdaptimmune Therapeutics2.119 of 5 stars$0.06-11.4%$1.35+2,080.1%-95.1%$16.43M$65.09M-0.10490Insider TradeGap UpHigh Trading VolumeEDSAEdesa Biotech1.5634 of 5 stars$2.32+2.2%$5.00+115.5%-46.1%$16.33MN/A-1.7620LPCNLipocine2.4829 of 5 stars$2.96-1.7%$9.00+204.1%-16.2%$16.04M$11.20M-3.4010News CoverageAnalyst ForecastAnalyst RevisionGap UpBLRXBioLineRx3.4297 of 5 stars$3.74-2.3%$26.00+595.2%-87.0%$15.93M$28.94M-0.4340MTEXMannatech0.2783 of 5 stars$8.36-2.3%N/A+18.8%$15.88M$112.98M-4.10250Gap UpLIXTLixte Biotechnology0.0498 of 5 stars$3.48-8.9%N/A+92.7%$15.87MN/A-2.704NRSNNeuroSense Therapeutics2.5636 of 5 stars$1.16-7.2%$14.00+1,106.9%+41.8%$15.86MN/A-2.1510News CoverageShort Interest ↑COCPCocrystal Pharma2.9066 of 5 stars$1.53-1.9%$6.00+292.2%-17.2%$15.70MN/A-1.2310News CoveragePositive NewsAnalyst RevisionATHAAthira Pharma3.8018 of 5 stars$0.40+1.3%$0.50+25.6%-87.2%$15.70MN/A-0.2640News CoveragePositive NewsAIMDAinos0.432 of 5 stars$3.34-0.3%N/A+10.2%$15.56M$110.87K-0.6740Short Interest ↑ Related Companies and Tools Related Companies ADAP Alternatives EDSA Alternatives LPCN Alternatives BLRX Alternatives MTEX Alternatives LIXT Alternatives NRSN Alternatives COCP Alternatives ATHA Alternatives AIMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access